MX2009012716A - Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. - Google Patents
Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.Info
- Publication number
- MX2009012716A MX2009012716A MX2009012716A MX2009012716A MX2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A MX 2009012716 A MX2009012716 A MX 2009012716A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- phenylpyrrolidines
- new disubstituted
- cortical
- catecholaminergic neurotransmission
- Prior art date
Links
- VDQQJMHXZCMNMU-UHFFFAOYSA-N 1-phenylpyrrolidine Chemical class C1CCCN1C1=CC=CC=C1 VDQQJMHXZCMNMU-UHFFFAOYSA-N 0.000 title 1
- 230000000768 catecholaminergic effect Effects 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000003943 catecholamines Chemical class 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 210000005171 mammalian brain Anatomy 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94199307P | 2007-06-05 | 2007-06-05 | |
| SE0701386 | 2007-06-05 | ||
| PCT/EP2008/056912 WO2008148799A1 (en) | 2007-06-05 | 2008-06-04 | New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012716A true MX2009012716A (es) | 2009-12-14 |
Family
ID=39672106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012716A MX2009012716A (es) | 2007-06-05 | 2008-06-04 | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100197760A1 (enExample) |
| EP (1) | EP2155669B1 (enExample) |
| JP (1) | JP2010529080A (enExample) |
| CN (1) | CN101711234A (enExample) |
| AT (1) | ATE508110T1 (enExample) |
| AU (1) | AU2008258597A1 (enExample) |
| CA (1) | CA2689692A1 (enExample) |
| DE (1) | DE602008006720D1 (enExample) |
| MX (1) | MX2009012716A (enExample) |
| NZ (1) | NZ581363A (enExample) |
| WO (1) | WO2008148799A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155671B8 (en) | 2007-06-05 | 2018-02-21 | Integrative Research Laboratories Sweden AB | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| WO2010058017A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| EP2367787B1 (en) | 2008-11-24 | 2013-01-09 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| CA2831435C (en) * | 2011-03-31 | 2018-05-01 | Chevron U.S.A. Inc. | Novel process and catalyst system for improving dewaxing catalyst stability and lubricant oil yield |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US364414A (en) * | 1887-06-07 | Gael hollweg | ||
| US2878264A (en) * | 1959-03-17 | Substituted amino alcohols | ||
| US3118907A (en) * | 1961-08-14 | 1964-01-21 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
| US3647790A (en) * | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
| EP0641320B1 (en) | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
| US5129962A (en) * | 1991-10-22 | 1992-07-14 | International Business Machines Corporation | Tacky, no-clean thermally dissipated soldering flux |
| US20020169155A1 (en) * | 1998-09-04 | 2002-11-14 | Millennium Pharmaceuticals, Inc. | Chemokine receptor anagonists and methods of use therefor |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| TWI308976B (en) * | 2003-02-14 | 2009-04-21 | Chunghwa Picture Tubes Ltd | Process and structure of linquid crystal panel with one drop fill |
| EA200701782A3 (ru) * | 2003-04-24 | 2008-04-28 | Инсайт Корпорейшн | Производные азаспироалканов в качестве ингибиторов металлопротеаз |
| CN1902177A (zh) * | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
| TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| KR100690854B1 (ko) * | 2005-11-08 | 2007-03-09 | 엘지전자 주식회사 | 멀티태스킹이 가능한 휴대용 단말기 및 그의 멀티태스킹처리방법 |
| CA2626220A1 (en) * | 2005-12-21 | 2007-06-28 | Janssen Pharmaceutica N.V. | Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases |
| US20080070649A1 (en) * | 2006-09-06 | 2008-03-20 | Uchida Toshi K | Free Space Optical Interconnections in Cellular Telephone Handsets |
-
2008
- 2008-06-04 US US12/663,211 patent/US20100197760A1/en not_active Abandoned
- 2008-06-04 AT AT08760493T patent/ATE508110T1/de not_active IP Right Cessation
- 2008-06-04 EP EP08760493A patent/EP2155669B1/en not_active Not-in-force
- 2008-06-04 NZ NZ581363A patent/NZ581363A/en unknown
- 2008-06-04 WO PCT/EP2008/056912 patent/WO2008148799A1/en not_active Ceased
- 2008-06-04 MX MX2009012716A patent/MX2009012716A/es active IP Right Grant
- 2008-06-04 CN CN200880018786A patent/CN101711234A/zh active Pending
- 2008-06-04 DE DE602008006720T patent/DE602008006720D1/de active Active
- 2008-06-04 CA CA2689692A patent/CA2689692A1/en not_active Abandoned
- 2008-06-04 JP JP2010510782A patent/JP2010529080A/ja active Pending
- 2008-06-04 AU AU2008258597A patent/AU2008258597A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2155669A1 (en) | 2010-02-24 |
| CA2689692A1 (en) | 2008-12-11 |
| JP2010529080A (ja) | 2010-08-26 |
| WO2008148799A1 (en) | 2008-12-11 |
| ATE508110T1 (de) | 2011-05-15 |
| CN101711234A (zh) | 2010-05-19 |
| DE602008006720D1 (de) | 2011-06-16 |
| EP2155669B1 (en) | 2011-05-04 |
| NZ581363A (en) | 2011-10-28 |
| US20100197760A1 (en) | 2010-08-05 |
| AU2008258597A1 (en) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA98783C2 (en) | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| MY161854A (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MY157192A (en) | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands | |
| EP2498609A4 (en) | SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MY160907A (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| EA201171063A1 (ru) | Фармацевтические составы олмесартана | |
| MX2011013437A (es) | Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos. | |
| MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
| UY31760A (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa | |
| CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
| UA104152C2 (ru) | Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии | |
| MX2009012716A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. | |
| NZ737451A (en) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| CL2012000650A1 (es) | Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |